Chelation therapy in cardiovascular disease: an update

References

• Cao Y, Skaug MA, Andersen O, et al. Chelation therapy in intoxications with mercury, lead and copper. J Trace Elem Med Biol. 2015;31:188–192.
   PubMed Web of Science ®Google Scholar
• Mitka M. Chelation therapy trials halted. Jama. 2008;300(19):2236.
   PubMed Web of Science ®Google Scholar
• Vogel JH, Bolling SF, Costello RB, et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College Of Cardiology Foundation Task Force On Clinical Expert Consensus Documents (Writing Committee To Develop An Expert Consensus Document On Complementary And Integrative Medicine). J Am Coll Cardiol. 2005;46(1):184–221.
   PubMed Web of Science ®Google Scholar
• Davis MA, Weeks WB. The concentration of out-of-pocket expenditures on complementary and alternative medicine in the United States. Altern Ther Health Med. 2012;18(5):36–42.
   PubMed Web of Science ®Google Scholar
• Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep. 2008 Dec 10;(12):1–23. PMID: 19361005.
   PubMedGoogle Scholar
• Chappell LT, Wilson J. Chelation therapy for vascular disease. Circulation. 1999;99(1):164–165.
   PubMed Web of Science ®Google Scholar
• Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J. 2000;140(1):4–5.
   PubMed Web of Science ®Google Scholar
• Clarke CN, Clarke NE, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci. 1956;232(6):654–666.
   PubMed Web of Science ®Google Scholar
• Meltzer LE. Chelation Therapy. Metal binding in medicine. Philadelphia (PA): JB Lipincott; 1960. p. 132–148.
   Google Scholar
• Clarke NE Sr, Clarke NE Jr, Mosher RE. Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci. 1960;239:732–744.
   PubMed Web of Science ®Google Scholar
• Kitchell JR, Meltzer LE, Seven MJ. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis. 1961;3:338–349.
   PubMed Web of Science ®Google Scholar
• Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology. 1964;15:379–395.
   PubMed Web of Science ®Google Scholar
• Lamar CP. Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc. 1966;14(3):272–294.
   PubMed Web of Science ®Google Scholar
• Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27(1):41–49.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Hubacek J, Wyse DG, et al. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. J Am Coll Cardiol. 2003;41(3):420–425.
   PubMed Web of Science ®Google Scholar
• Guldager B, Jelnes R, Jørgensen SJ, et al. EDTA treatment of intermittent claudication – a double-blind, placebo-controlled study. J Intern Med. 1992;231(3):261–267.
   PubMed Web of Science ®Google Scholar
• Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA. 2002;287(4):481–486.
   PubMed Web of Science ®Google Scholar
• Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991;162(2):122–125.
   PubMed Web of Science ®Google Scholar
• van Rij AM, Solomon C, Packer SG, et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation. 1994;90(3):1194–1199.
   PubMed Web of Science ®Google Scholar
• Lamas GA, Navas-Acien A, Mark DB, et al. Heavy metals, cardiovascular disease, and the unexpected benefits of chelation therapy. J Am Coll Cardiol. 2016;67(20):2411–2418.
   PubMed Web of Science ®Google Scholar
• Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241–1250.
   PubMed Web of Science ®Google Scholar
• Kitchell JR, Palmon F Jr, Aytan N, et al. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiol. 1963;11:501–506.
   PubMed Web of Science ®Google Scholar
• EDTA chelation therapy for arteriosclerotic heart disease. Med Lett Drugs Ther. 1981;23(11):51. PMID: 6785565.
   Google Scholar
• Robinson DM. Chelation therapy. N Z Med J. 1982;95(718):750.
   PubMed Web of Science ®Google Scholar
• Casdorph HR, Farr CH. EDTA chelation therapy. III. Treatment of peripheral arterial occlusion, an alternative to amputation. J Holistic Med. 1983;5:3–15.
   Google Scholar
• Godfrey ME. EDTA chelation as a treatment of arteriosclerosis. N Z Med J. 1990;103(887):162–163.
   PubMed Web of Science ®Google Scholar
• Casdorph HR. EDTA chelation therapy – efficacy in arteriosclerotic heart disease. J Holistic Med. 1981;3:101–117.
   Google Scholar
• Riordan HD, Cheraskin E, Dirks M, et al. EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthomolecular Med. 1989;4:91–95.
   Google Scholar
• Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother. 1993;27(12):1504–1509.
   PubMed Web of Science ®Google Scholar
• Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med. 1993;6:139–160.
   Google Scholar
• Elihu N, Anandasbapathy S, Frishman WH. Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol. 1998;38(2):101–105.
   PubMed Web of Science ®Google Scholar
• Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114(13):1388–1394.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Jain N, Nie H, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation. 2009;120(12):1056–1064. Erratum in: Circulation. 2014;130(5):e43.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Zaman T, Tuzcu EM, et al. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. Angiology. 2011;62(5):422–429.
   PubMed Web of Science ®Google Scholar
• Messner B, Bernhard D. Cadmium and cardiovascular diseases: cell biology, pathophysiology, and epidemiological relevance. Biometals. 2010;23(5):811–822.
   PubMed Web of Science ®Google Scholar
• Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12(11):627–642.
   PubMed Web of Science ®Google Scholar
• Hanna CW, Bloom MS, Robinson WP, et al. DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. Hum Reprod. 2012;27(5):1401–1410.
   PubMed Web of Science ®Google Scholar
• Ruiz-Hernandez A, Kuo CC, Rentero-Garrido P, et al. Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence. Clin Epigenetics. 2015;7:55.
   PubMed Web of Science ®Google Scholar
• Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med. 2014;24(6):232–240.
   PubMed Web of Science ®Google Scholar
• Deucher DP. EDTA chelation: an antioxidant strategy. J Adv Med. 1988;1:182–190.
   Google Scholar
• Waters RS, Bryden NA, Patterson KY, et al. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res. 2001;83(3):207–221.
   PubMed Web of Science ®Google Scholar
• Kindness G, Frackelton JP. Effect of ehtylene diamine tetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med. 1989;2:519–530.
   Google Scholar
• Green DJ, O’Driscoll JG, Maiorana A, et al. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin Exp Pharmacol Physiol. 1999;26(11):853–856.
   PubMed Web of Science ®Google Scholar
• Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc. 1990;82(3):173–177.
   PubMed Web of Science ®Google Scholar
• Guldager B, Faergeman O, Jørgensen SJ, et al. Disodium-ethylene diamine tetraacetic acid (EDTA) has no effect on blood lipids in atherosclerotic patients. A randomized, placebo-controlled study. Dan Med Bull. 1993;40(5):625–627.
   PubMed Web of Science ®Google Scholar
• Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2002;(4):CD002785. PMID: 12519577.
   PubMedGoogle Scholar
• Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord. 2005;5:32.
   PubMedGoogle Scholar
• U.S. National Institutes of Health Clinical Trials.gov [Internet]. Trial to Assess Chelation Therapy 2 (TACT2); November 2016 Available from: https://clinicaltrials.gov/ct2/show/record/NCT02733185?term=TACT+2&rank=1.
   Google Scholar
• Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014;7(1):15–24.
   PubMed Web of Science ®Google Scholar
• Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). JAMA. 2013;309(12):1293–1294.
   PubMed Web of Science ®Google Scholar
• Mark DB, Anstrom KJ, Clapp-Channing NE, et al. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. Circ Cardiovasc Qual Outcomes. 2014;7(4):508–516.
   PubMed Web of Science ®Google Scholar
• Berkman N, Michaeli Y, Or R, et al. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol. 1991;36(3):195–201.
   PubMed Web of Science ®Google Scholar
• Peterson GR. Adverse effects of chelation therapy. JAMA. 1983;250(21):2926.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy – Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep. 2006;55(8):204–207.
   PubMedGoogle Scholar
• Whayne TF Jr. What should medical practitioners know about the role of alternative medicines in cardiovascular disease management? Cardiovasc Ther. 2010;28(2):106–123.
   PubMed Web of Science ®Google Scholar
• Atwood KC, Woeckner E, Baratz RS, et al. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned. Medscape J Med. 2008;10(5):115.
   PubMedGoogle Scholar
• Commonwealth of Pennsylvania Bureau of Professional and Occupational Affairs vs. Roy Eugene Kerry, MD, Respondent. September 8, 2006. Available from: http://www.circare.org/pd/kerry_ordertoshowcause_20060908.pdf
   Google Scholar
• U.S. Food and Drug Administration. Silver Spring, MD: U.S. Department of Health and Human Services. cited 2017 Jan. 30. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051138.htm
   Google Scholar
• Lamas GA, Hussein SJ. EDTA chelation therapy meets evidence-based medicine. Complement Ther Clin Pract. 2006;12(3):213–215.
   PubMedGoogle Scholar
• Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy. 2002;22(8):1067–1069.
   PubMed Web of Science ®Google Scholar
• Choosing Wisely. Philadelphia, PA: ABIM Foundation. cited 2016 Oct. 24. Available from: http://www.choosingwisely.org/societies/american-college-of-medical-toxicology-and-the-american-academy-of-clinical-toxicology
   Google Scholar
• Allain P, Mauras Y, Premel-Cabic A, et al. Effects of an EDTA infusion on the urinary elimination of several elements in healthy subjects. Br J Clin Pharmacol. 1991;31(3):347–349.
   PubMed Web of Science ®Google Scholar
• Monaco GP, Green S. Recognizing deception in the promotion of untested and unproven medical treatments. N Y State J Med. 1993;93(2):88–91.
   PubMedGoogle Scholar
• Federal Trade Commission. Washington (DC): Federal Trade Commission. cited 2017 Jan. 30. Available from: https://www.ftc.gov/news-events/press-releases/1998/12/medical-association-settles-false-advertising-charges-over
   Google Scholar
• U.S. Food and Drug Administration. Silver Spring, MD: U.S. Department of Health and Human Services. cited 2017 Jan. 30. Available from: http://www.fda.gov/forconsumers/consumerupdates/ucm229358.htm
   Google Scholar
• Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64(18):1929–1949.
   PubMed Web of Science ®Google Scholar
• Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116(23):2762–2772. Erratum in: Circulation. 2007;116(23):e558.Pasternak, Richard C [removed].
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):3097–3137. Erratum in: Circulation. 2014;129(16):e462.
   PubMed Web of Science ®Google Scholar
• Cardio Renew. Apple Valley, MN: Cardio Renew. cited 2017 Jan 30. Available from: http://www.cardiorenew.com/chelation.php
   Google Scholar
• The Center for Natural & Integrative Medicine. Orlando, FL: The Center for Natural & Integrative Medicine. cited 2017 Jan 30. Available from:: http://www.drkalidas.com/pathways/chelation.html
   Google Scholar
• Aydinok Y, Kattamis A, Viprakasit V. Current approach to iron chelation in children. Br J Haematol. 2014;165:745–755.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733–3737.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96:41–47.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (London, England). 2002;360:516–520.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy. J Cardiovasc Magn Reson. 2013;15:1.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011;47(1):33–40.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Carpenter JP, Roughton M, et al. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45.
   PubMed Web of Science ®Google Scholar
• Porcu M, Landis N, Salis S, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail. 2007;9(3):320–322.
   PubMed Web of Science ®Google Scholar
• Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85(2):393–400.
   PubMed Web of Science ®Google Scholar
• Link G, Saada A, Pinson A, et al. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med. 1998;131(5):466–474.
   PubMed Web of Science ®Google Scholar
• Lesnefsky EJ, Moghaddas S, Tandler B, et al. Mitochondrial dysfunction in cardiac disease: ischemia – reperfusion, aging, and heart failure. J Mol Cell Cardiol. 2001;33(6):1065–1089.
   PubMed Web of Science ®Google Scholar
• Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219–5227.
   PubMed Web of Science ®Google Scholar
• Xu LJ, Jin L, Pan H, et al. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin. 2006;27(10):1333–1339.
   PubMed Web of Science ®Google Scholar
• Ammar E-SM, Said SA, Suddek GM, et al. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Can J Physiol Pharmacol. 2011;89(4):269–276.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87(7):545–550.
   PubMed Web of Science ®Google Scholar
• Galia M, Midiri M, Bartolotta V, et al. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study. Hemoglobin. 2003;27(2):63–76.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood. 1997;90:264a.
   Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
   PubMed Web of Science ®Google Scholar
• Kuo KH, Mrkobrada M. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Hemoglobin. 2014;38(6):409–421.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Brunskill SJ, Doree C, et al. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. PMID: 23963793.
   PubMed Web of Science ®Google Scholar
• Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9):1187–1192.
   PubMed Web of Science ®Google Scholar
• Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24(7):1905–1917.
   PubMed Web of Science ®Google Scholar
• Payne KA, Rofail D, Baladi JF, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25(8):725–742.
   PubMed Web of Science ®Google Scholar
• Rofail D, Viala M, Gater A, et al. An instrument assessing satisfaction with iron chelation therapy: psychometric testing from an open-label clinical trial. Adv Ther. 2010;27(8):533–546.
   PubMed Web of Science ®Google Scholar
• Vekeman F, Sasane M, Cheng WY, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016;19(3):292–303.
   PubMed Web of Science ®Google Scholar